Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe

H H Feldman, R S Doody, M Kivipelto, D L Sparks, D D Waters, R W Jones, E Schwam, R Schindler, J Hey-Hadavi, D A DeMicco, A Breazna, LEADe Investigators, Peter Passmore

Research output: Contribution to journalArticle

306 Citations (Scopus)

Abstract

There is some evidence that statins may have a protective and symptomatic benefit in Alzheimer disease (AD). The LEADe study is a randomized controlled trial (RCT) evaluating the efficacy and safety of atorvastatin in patients with mild to moderate AD.
Original languageEnglish
Pages (from-to)956-64
Number of pages9
JournalNeurology
Volume74
Issue number12
DOIs
Publication statusPublished - Mar 2010

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe'. Together they form a unique fingerprint.

  • Cite this

    Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., Breazna, A., LEADe Investigators, & Passmore, P. (2010). Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology, 74(12), 956-64. https://doi.org/10.1212/WNL.0b013e3181d6476a